Our 150+ page report provides 41 tables, 43 charts and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Sarcoma Drugs market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
– You find original analyses, with business outlooks and developments.
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 2 segmentations of the Treatment Type, each forecasted at a global and regional level.
Global Sarcoma Drugs Market by Treatment Type
– Chemotherapy
– Targeted Therapy
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:
– North America:
– US
– Canada
– Europe:
– Germany
– France
– UK
– Italy
– Spain
– Russia
– Rest of Europe
– Asia-Pacific:
– Japan
– China
– India
– Australia
– ASEAN
– Rest of Asia-Pacific
– Latin America:
– Brazil
– Mexico
– Rest of Latin America
– MEA:
– UAE
– South Africa
– Saudi Arabia
– Rest of MEA
The report also includes profiles and for some of the leading companies in the Sarcoma Drugs Market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Japan, India and China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth
Overall world revenue for Sarcoma Drugs will surpass $850 mn in 2020, our work calculates. We predict strong revenue growth through to 2030.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Sarcoma Drugs Market report helps you
In summary, our 150+ page report provides you with the following knowledge:
– Revenue forecasts to 2030 for 2 segmentations of the Sarcoma Drugs market, with forecasts for 4 Treatment Type, 3 End use, each forecasted at a global and regional level–discover the industry’s prospects, finding the most lucrative places for investments and revenues
– Revenue forecasts to 2030 for 5 regional and 18 key national markets – See forecasts for the Sarcoma Drugs market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, ASEAN countries, UAE, South Africa and Saudi Arabia.
– Stimulates and restrains companies and the market
– Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the Sarcoma Drugs market
– Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain study is for everybody needing commercial analyses for the Sarcoma Drugs market and leading companies. You will find data, trends and predictions.
Get our report today The Sarcoma Drugs Market Analysis : Revenue Prospects by Treatment Type (Chemotherapy, Targeted Therapy, Anti-angiogenesis drugs, Radiation Therapy), End use (Hospitals, Diagnostic Centers, Oncology Centers) and Geography.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Sarcoma Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Includes
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction
2.1 Objectives of the Study
2.2 Market Definition
2.3 Market Scope
2.4 Markets Covered
2.5 Years Considered for the Study
2.6 Limitations
2.7 Currency
3. Industry Insights
3.1 Market Drivers
3.1.1 Launch of novel drugs
3.1.2 Rising incidence of STS
3.1.3 Increasing R&D activities
3.1.4 Uptake of targeted therapies
3.1.5 Growing patient assistance programs (PAPS)
3.2 Market Restraints/Challenges
3.2.1 High cost for treatment and medication along with associated side effects
3.2.2 Reimbursement issues
3.2.3 Stringent government regulation
3.2.4 High failure rates
3.3 Market Opportunities
3.3.1 Late-stage pipeline products
3.3.2 Increasing focus on adapted medication
3.4 Value chain analysis
3.5 SWOT analysis (qualitative insights)
3.5.1 Sources of strengths which could be leveraged
3.5.2 Weaknesses to overcome & offset
3.5.3 Opportunities to capitalize upon
3.5.4 Threats to mitigate
3.6 PEST analysis (qualitative insights)
3.6.1 Political factors
3.6.1.1 Description and overview of political factors
3.6.1.2 Definition and identification of relevant political factors
3.6.1.3 Political concerns
3.6.1.4 Reforms and Regulations
3.6.1.5 Political stability
3.6.2 Economic factors
3.6.2.1 Definition and identification of economic factors
3.6.2.2 Description and overview of economic factors
3.6.2.3 Economic concerns
3.6.2.4 Economic value
3.6.2.5 Resource efficiency
3.6.3 Social factors
3.6.3.1 Description and overview of social factors
3.6.3.2 Definition and identification of social factors
3.6.3.3 Social concerns
3.6.3.4 Knowledge and skills
3.6.4 Technological factors
3.6.4.1 Description and overview of technological factors
3.6.4.2 Definition and identification of technological factors
3.6.4.3 Technological concerns
3.7 Porters Five Forces Model (qualitative insights)
3.7.1 Industrial competitors
3.7.1.1 Diversity of competitors
3.7.1.2 Industry concentration
3.7.1.3 Industry growth
3.7.1.4 Number of competitors
3.7.1.5 Concentration and balance
3.7.2 Threat of Substitutes
3.7.2.1 Buyer propensity to substitute
3.7.2.2 Relative price performance of substitutes
3.7.2.3 Switching costs
3.7.3 Bargaining Power of Buyers
3.7.3.1 Buyer's ability to substitute
3.7.3.2 Buyer's information availability
3.7.3.3 Difference between competitors
3.7.3.4 Number of customers
3.7.3.5 Price sensitivity
3.7.4 Bargaining Power of Suppliers
3.7.4.1 Presence of substitute inputs
3.7.4.2 Supplier concentration
3.7.4.3 Switching cost of suppliers and firms in the industry
3.7.4.4 Threat of forward integration relative to threat of backward integration by firms in the industry
3.7.5 Threat of New Entrants
3.7.5.1 Access to distribution channel
3.7.5.2 Barriers to entry
3.7.5.3 Brand loyalty
3.7.5.4 Capital requirements
3.7.5.5 Economies of scale
3.7.5.6 Government policies
3.7.5.7 Switching costs
3.8 Patent Analysis
4. Global Sarcoma Drugs market – Pipeline Analysis
4.1 Pipeline Landscape
4.1.1 Leading Drugs in Development
4.2 Key R&D Trends
4.2.1 Chemotherapy
4.2.2 Immunotherapy
4.2.2.1 Cancer Vaccines
4.2.2.2 Gene Therapy
4.2.2.3 Immuno-oncology agents
4.2.3 Targeted Therapy
4.3 Pipeline Landscape
4.3.1 Late Stage Pipeline Drugs
4.4 Clinical Profiles of Disruptive Drugs
4.5 Global Pipeline Forecast
5. Global Sarcoma Drugs market – By Treatment Type
5.1 Chemotherapy
5.1.1 Market size and forecast, 2020-2030 (USD Million)
5.2 Targeted Therapy
5.2.1 Market size and forecast, 2020-2030 (USD Million)
6. By Region
6.1 Introduction
6.2 North America Sarcoma Drugs market, 2020-2030 (USD Million)
6.2.1 U.S.
6.2.1.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.2.2 Canada
6.2.2.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3 Europe Sarcoma Drugs market, 2020-2030 (USD Million)
6.3.1 Germany
6.3.1.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.2 France
6.3.2.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.3 UK
6.3.3.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.4 Italy
6.3.4.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.5 Spain
6.3.5.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.6 Russia
6.3.6.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.3.7 Rest of Europe
6.3.7.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4 Asia-Pacific Sarcoma Drugs market, 2020-2030 (USD Million)
6.4.1 Japan
6.4.1.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4.2 China
6.4.2.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4.3 India
6.4.3.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4.4 Australia
6.4.4.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4.5 ASEAN
6.4.5.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.4.6 Rest of APAC
6.4.6.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.5 Latin America Sarcoma Drugs market, 2020-2030 (USD Million)
6.5.1 Brazil
6.5.1.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.5.2 Mexico
6.5.2.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.5.3 Rest of Latin America
6.5.3.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.6 Middle East Sarcoma Drugs Market, 2020-2030 (USD Million)
6.6.1 UAE
6.6.1.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.6.2 Saudi Arabia
6.6.2.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.6.3 South Africa
6.6.3.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
6.6.4 RoMEA
6.6.4.1 Market Size & Forecast, By Treatment Type, 2020-2030 (USD Million)
7. Competitive Landscape
7.1 Competitive environment
7.2 New product development
7.3 Merger & acquisitions
7.4 Strategic framework
8. Leading Companies
8.1 Bayer
8.1.1 Company Overview
8.1.2 Product Offerings
8.1.3 Financial Performance (2016-2018)
8.1.4 Recent Initiatives
8.1.5 Pipeline Analysis and Overview
8.2 Bristol-Myers Squibb
8.2.1 Company Overview
8.2.2 Product Offerings
8.2.3 Financial Performance (2016-2018)
8.2.4 Recent Initiatives
8.3 Celgene Corporation
8.3.1 Company Overview
8.3.2 Product Offerings
8.3.3 Financial Performance (2016-2018)
8.3.4 Recent Initiatives
8.4 Eisai
8.4.1 Company Overview
8.4.2 Product Offerings
8.4.3 Financial Performance (2016-2018)
8.4.4 Recent Initiatives
8.4.5 Pipeline Analysis and Overview
8.5 Eli Lilly and Company
8.5.1 Company Overview
8.5.2 Product Offerings
8.5.3 Financial Performance (2016-2018)
8.5.4 Recent Initiatives
8.5.5 Pipeline Analysis and Overview
8.6 Genentech USA
8.6.1 Company Overview
8.6.2 Product Offerings
8.6.3 Financial Performance (2016-2018)
8.6.4 Recent Initiatives
8.7 GlaxoSmithKline
8.7.1 Company Overview
8.7.2 Product Offerings
8.7.3 Financial Performance (2016-2018)
8.7.4 Recent Initiatives
8.8 Hoffmann-La Roche Ltd
8.8.1 Company Overview
8.8.2 Product Offerings
8.8.3 Financial Performance (2016-2018)
8.8.4 Recent Initiatives
8.9 Johnson & Johnson Services, Inc.
8.9.1 Company Overview
8.9.2 Product Offerings
8.9.3 Financial Performance (2016-2018)
8.9.4 Recent Initiatives
8.9.5 Pipeline Analysis and Overview
8.10 Novartis
8.10.1 Company Overview
8.10.2 Product Offerings
8.10.3 Financial Performance (2016-2018)
8.10.4 Recent Initiatives
8.10.5 Pipeline Analysis and Overview
8.11 Pfizer, Inc.
8.11.1 Company Overview
8.11.2 Product Offerings
8.11.3 Financial Performance (2016-2018)
8.11.4 Recent Initiatives
8.11.5 Pipeline Analysis and Overview
8.12 Teva Pharmaceuticals
8.12.1 Company Overview
8.12.2 Product Offerings
8.12.3 Financial Performance (2016-2018)
8.12.4 Recent Initiatives
9. Appendix
9.1 Insights of Industry Experts
9.2 Related Reports
9.3 Author Details
9.4 Available Customizations
LIST OF TABLES
Table 1 Global Sarcoma Drugs Market Size, By Region, 2020-2030 (USD Mn, CAGR%)
Table 2 Global Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 3 North America: Sarcoma Drugs Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 4 North America: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 5 US: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 6 Canada: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 7 Europe: Sarcoma Drugs Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 8 Europe: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 9 Germany: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 10 France: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 11 UK: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 12 Italy: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 13 Spain: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 14 Russia: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 15 Rest of Europe: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 16 Asia-Pacific: Sarcoma Drugs Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 17 Asia-Pacific: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 18 Japan: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 19 China: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 20 India: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 21 Australia: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 22 ASEAN: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 23 Rest of APAC: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 24 Latin America: Sarcoma Drugs Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 25 Latin America: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 26 Brazil: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 27 Mexico: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 28 Rest of Latin America: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 29 MEA: Sarcoma Drugs Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 30 MEA: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 31 UAE: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 32 Saudi Arabia: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 33 South Africa: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 34 Rest of MEA: Sarcoma Drugs Market Size, By Treatment Type, 2020-2030 (USD Mn, CAGR%)
Table 35 Pipeline Forecast
Table 36 Bayer Product Forecast Sales, (2018-2022)
Table 37 Johnson & Johnson Product Forecast Sales, (2018-2022)
Table 38 Eisai - Product Forecast Sales, (2018-2022)
Table 39 Eli Lilly Product Forecast Sales, (2018-2022)
Table 40 Pfizer Product Forecast Sales, (2018-2022)
Table 41 Novartis Product Forecast Sales, (2018-2022)
LIST OF FIGURES
Figure 1 Sarcoma Major Subtypes
Figure 2 Global Sarcoma Drugs Market Segmentation
Figure 3 Global Sarcoma Drugs Market: Market Dynamics
Figure 4 Global Sarcoma Drugs Market Porter’s analysis
Figure 5 Global Sarcoma Drugs Market PEST analysis
Figure 6 Drivers, Restraints, Opportunities, and Challenges in the Global Sarcoma Drugs Market
Figure 7 Global Sarcoma Drugs Market, By Treatment Type, 2020-2030 (USD Mn)
Figure 8 Global Sarcoma Drugs Market, By Region, 2018 & 2030 (%)
Figure 9 North America Sarcoma Drugs Market, By Country, 2018 & 2030 (%)
Figure 10 U.S. Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 11 Canada Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 12 Europe Sarcoma Drugs Market, By Country, 2018 & 2030 (%)
Figure 13 Germany Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 14 UK Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 15 France Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 16 Italy Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 17 Spain Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 18 Russia Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 19 Rest of Europe Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 20 APAC Sarcoma Drugs Market, By Country, 2018 & 2030 (%)
Figure 21 Japan Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 22 China Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 23 Australia Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 24 ASEAN Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 25 Rest of APAC Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 26 Latin America Sarcoma Drugs Market, By Country, 2018 & 2030 (%)
Figure 27 Brazil Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 28 Mexico Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 29 Rest of Latin America Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 30 MEA Sarcoma Drugs Market, By Country, 2018 & 2030 (%)
Figure 31 UAE Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 32 Saudi Arabia Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 33 South Africa Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 34 Rest of MEA Sarcoma Drugs Market, 2020-2030 (USD Mn)
Figure 35 Company Share Analysis, 2018
Figure 36 Recent Development, 2016-2018
Figure 37 Novartis SWOT Analysis
Figure 38 Eli Lilly SWOT Analysis
Figure 39 Bayer SWOT Analysis
Figure 40 Johnson & Johnson SWOT Analysis
Figure 41 Eisai SWOT Analysis
Figure 42 Pfizer SWOT Analysis
Figure 43 Global Sarcoma Drugs Market Concentration Rate